Home » Genzyme Wait for Higher Bid Risky Due to FDA Plant Deadline, Orbimed Says
Genzyme Wait for Higher Bid Risky Due to FDA Plant Deadline, Orbimed Says
Genzyme Corp.’s wait for a takeover offer higher than Sanofi-Aventis SA’s hostile bid is risky because of the biotechnology company’s manufacturing record, shareholder OrbiMed Advisors LLC said.
Bloomberg
Bloomberg
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May